DACARBAZINE
No Prior Chemotherapy
University of ZurichSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the No Prior Chemotherapy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sorafenib University of Zurich | Phase 2 | B |
Carboplatin David O'Malley | Phase 1 | CC |
Irinotecan David O'Malley | Phase 1 | CC |
(+)-VINCRISTINE David O'Malley | Phase 1 | CC |
Same molecule, other indications
DACARBAZINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →